<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Drug-induced neutropenia and agranulocytosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Drug-induced neutropenia and agranulocytosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Drug-induced neutropenia and agranulocytosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas D Coates, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter Newburger, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 21, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Most cases of neutropenia in adults are acquired and are due to decreased granulocyte production or increased destruction. Neutropenia can be predictable and dose related, as in the case of cytotoxic chemotherapy, or an idiosyncratic reaction. The mechanisms of the neutropenia are varied and the propensity to infection depends upon the adequacy of bone marrow reserve.</p><p>Drug-induced neutropenia and agranulocytosis will be reviewed here. Others causes of acquired neutropenia, such as primary immune mechanisms, chemotherapy, and infections, as well as congenital neutropenia in children are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8371.html" rel="external">"Immune neutropenia"</a> and  <a class="medical medical_review" href="/z/d/html/8372.html" rel="external">"Infectious causes of neutropenia"</a> and  <a class="medical medical_review" href="/z/d/html/8373.html" rel="external">"Congenital neutropenia"</a> and  <a class="medical medical_review" href="/z/d/html/16708.html" rel="external">"Overview of neutropenic fever syndromes"</a>.)</p><p>The overall approach to the patient with neutropenia is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8375.html" rel="external">"Overview of neutropenia in children and adolescents"</a> and  <a class="medical medical_review" href="/z/d/html/90654.html" rel="external">"Approach to the adult with unexplained neutropenia"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>Neutropenia is defined as an absolute neutrophil count (ANC) &lt;1500/microL. The ANC is numerically equal to the product of the white blood cell count (WBC) and the fraction of polymorphonuclear cells (PMNs) and band forms noted on the differential analysis (<a class="calc calc_professional" href="/z/d/html/13483.html" rel="external">calculator 1</a>):</p><div class="formulaContainer"><div class="formula"><p class="bulletIndent1">ANC = (WBC [cells/microL] x percent [PMNs + bands]) ÷ 100</p></div></div><p></p><p>As an example, a patient with a total WBC of 3500/microL, 30 percent PMNs and 1 percent bands would have an ANC = (3500 x [30 + 1]) ÷ 100 = 1085/microL.</p><p>Neutrophilic metamyelocytes and younger forms are not included in this calculation. The risk of infection increases when the ANC falls to less than 1000/microL, and is most clinically significant when the ANC is &lt;500/microL  (<a class="graphic graphic_table graphicRef63903" href="/z/d/graphic/63903.html" rel="external">table 1</a>).</p><p>The terms leukopenia and granulocytopenia are generally used interchangeably with neutropenia, although they are somewhat different. Leukopenia refers specifically to a low WBC due to any cause, while granulocytopenia refers to a reduced number of granulocytes.</p><p>Agranulocytosis literally means the absence of granulocytes (ie, ANC of zero), although the term is often used loosely to indicate severe degrees of neutropenia (ie, ANC &lt;100, &lt;200 or even &lt;500/microL) [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H5"><span class="h1">DRUG-INDUCED NEUTROPENIA</span></p><p class="headingAnchor" id="H1988661064"><span class="h2">Epidemiology</span><span class="headingEndMark"> — </span>Idiosyncratic drug reactions (IDR) have an estimated incidence of 1/10,000 to 1/100,000 [<a href="#rid2">2</a>]. However, since many drugs have associated idiosyncratic drug reactions, the overall risk is higher. While the risk is independent of dose, they are more common in drugs given at high dose and very rarely seen if the dose is less than 10 mg/day. </p><p class="headingAnchor" id="H6"><span class="h2">Implicated agents</span><span class="headingEndMark"> — </span>A number of medications have been implicated as potential causes of severe neutropenia or agranulocytosis. Evidence for such a relationship is based upon an accumulation of case reports, spontaneous reports to registries, cohort studies, and population and case control studies. Drugs can be classified as definite, probable, or possible causes of neutropenia based upon the available evidence.</p><p>There are a number of medications that are considered to have a high risk for agranulocytosis based upon definite and unequivocal evidence  (<a class="graphic graphic_table graphicRef65507" href="/z/d/graphic/65507.html" rel="external">table 2</a>) [<a href="#rid3">3-6</a>]. This list excludes agents that produce agranulocytosis on the basis of bone marrow suppression (eg, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a>, <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">ganciclovir</a>).</p><p>Among the agents that are more commonly associated with agranulocytosis are <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>, the thionamides (antithyroid drugs), <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a>, and <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">ticlopidine</a>. Other classes of agents with multiple reports of agranulocytosis include other antibiotics [<a href="#rid7">7</a>], ACE inhibitors [<a href="#rid4">4,8,9</a>], H2 blockers [<a href="#rid10">10-12</a>], nonsteroidal antiinflammatory drugs [<a href="#rid13">13-19</a>], amodiaquine [<a href="#rid20">20,21</a>], antiarrhythmic drugs such as tocainide, <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">procainamide</a>, and <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a> [<a href="#rid22">22-25</a>], aminoglutethimide (no longer available) [<a href="#rid26">26,27</a>], <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> [<a href="#rid28">28</a>], and <a class="drug drug_general" data-topicid="17092" href="/z/d/drug information/17092.html" rel="external">deferiprone</a> [<a href="#rid29">29,30</a>].</p><p>In a systematic literature review of English- and German-language reports of patients with non-chemotherapy drug-induced agranulocytosis, the following 11 drugs accounted for more than 50 percent of definite or probable reports: carbimazole, <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>, <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>, dipyrone, <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a>, <a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">penicillin G</a>, <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">procainamide</a>, <a class="drug drug_general" data-topicid="9830" href="/z/d/drug information/9830.html" rel="external">propylthiouracil</a>, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a>, and <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">ticlopidine</a> [<a href="#rid1">1</a>]. A listing of all case reports of agranulocytosis included in this 2007 systematic review is available at: <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.adverse-effects.com%2Fagranulocytosis%2Fcase_reports.html&amp;token=EyNdp%2BeUcuia4XYgAMFdcFPfCCUC6yOpDYUP5hoCgX02ORjwXKrzrBMjJKi%2FHzN37j2fIGfO1RgwrFPHf%2Bs44nhPTNt1EzyEnhZ1St%2FTMC4%3D&amp;TOPIC_ID=8374" target="_blank">www.adverse-effects.com/agranulocytosis/case_reports.html</a> [<a href="#rid31">31</a>].</p><p>The relative and absolute risks of drug-induced agranulocytosis were evaluated in a study of all patients hospitalized in the Netherlands for a diagnosis of agranulocytosis (defined as an ANC &lt;500/microL) during the years 1987 through 1990. The following results were found [<a href="#rid6">6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The highest relative risks for development of agranulocytosis were found for antithyroid drugs, <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a>, <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, dipyrone combined with analgesics, <a class="drug drug_general" data-topicid="9283" href="/z/d/drug information/9283.html" rel="external">clomipramine</a>, and carbimazole.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Three drugs (<a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a>, <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a>, and <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>) were responsible for 42 percent of all cases, with excess risks (cases of agranulocytosis per million users following 10 days of exposure) of 10.1, 3.6, and 1.2, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Calcium dobesilate (Doxium), a veno-tonic drug widely prescribed in Europe, Latin America, Asia, and the Middle East, has been associated with a high incidence of agranulocytosis [<a href="#rid32">32</a>].</p><p></p><p class="headingAnchor" id="H7"><span class="h2">Psychotropic drugs and anticonvulsants</span><span class="headingEndMark"> — </span>Many psychotropic agents, such as <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>, the phenothiazines and the tri- and tetra-cyclic antidepressants, have been associated with neutropenia and/or agranulocytosis. Similarly, many of the commonly used anticonvulsants can cause hypersensitivity reactions (eg, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>) and are associated with neutropenia. Clinicians need to be aware of this possibility and either monitor blood counts in patients taking such agents on a regular basis or alert the patient to the possibility that fever and/or infection may be signs of this toxicity. (See  <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Carbamazepine'</a>.)</p><p class="headingAnchor" id="H8"><span class="h3">Clozapine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">Clozapine</a>, an atypical antipsychotic agent, is used only for schizophrenia unresponsive to other therapies due to the risk of agranulocytosis [<a href="#rid3">3,5,33</a>]. The cumulative risk of agranulocytosis is approximately 0.8 to 1.5 percent at one year [<a href="#rid3">3,33</a>], with little further increase over time [<a href="#rid3">3</a>]. The majority of cases (84 percent) occur within the first three months of therapy, which constitutes the rationale for monitoring the white blood cell count, especially soon after therapy has been instituted. (See <a class="local">'Prevention and screening'</a> below and  <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">"Second-generation antipsychotic medications: Pharmacology, administration, and side effects"</a>.)</p><p class="headingAnchor" id="H9"><span class="h3">Olanzapine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">Olanzapine</a>, related structurally to <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>, has been recommended as an antipsychotic agent for patients with clozapine-induced granulocytopenia or agranulocytosis. However, the safety of this approach is uncertain due in part to the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>Metabolites of <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> were toxic in vitro to neutrophils from two patients with a history of clozapine-induced agranulocytosis [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One patient developed agranulocytosis following treatment with <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>; he had been treated previously with <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> without hematologic complications [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another patient with clozapine-induced neutropenia developed reversible neutropenia after being switched to <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> [<a href="#rid36">36</a>].</p><p></p><p class="headingAnchor" id="H1033710"><span class="h2">Deferiprone</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="17092" href="/z/d/drug information/17092.html" rel="external">Deferiprone</a> is an oral iron-chelating agent that has been in use since the 1990s [<a href="#rid29">29</a>]. It has been available in many European countries for a number of years [<a href="#rid29">29,30</a>] and was approved for use in the United States in 2011 [<a href="#rid37">37</a>]. Agranulocytosis has been reported in 0.5 to 3.6 percent of patients in various studies [<a href="#rid29">29</a>]. An ANC of less than 0.2 x 10<sup>9</sup>/L was seen in 0.2/100 patient years and 0.5 to 1500 x 10<sup>9</sup>/L in 2.8 per 100 patient years [<a href="#rid30">30</a>]. The onset of agranulocytosis or neutropenia can occur between zero and 19 months or zero and 70 months, respectively, but usually occurs in the first year after starting the drug. </p><p>Both neutropenia and agranulocytosis are reversible after stopping the drug. While some patients with neutropenia have done well after restarting the drug, it is recommended that patients will full agranulocytosis not be rechallenged with this agent. There have been reported deaths from sepsis due to agranulocytosis. At close inspection of these cases, the physicians and patients were not aware of the possibility of this side effect and therefore did not respond properly when fever developed. Because of this risk, it is recommended that monitoring of the ANC be performed in all patients taking the medication, and they be instructed to stop the drug and seek medical attention if there is any development of fever [<a href="#rid29">29,37,38</a>].</p><p>A report of fatal aplasia in a patient with Diamond-Blackfan anemia [<a href="#rid39">39</a>] has led to concern regarding the use of this agent in patients with marrow failure syndromes. The mechanism of the agranulocytosis is unclear, though it is likely different from that of milder neutropenia. Bone marrow examination has shown early myeloid arrest at the progranulocyte stage [<a href="#rid40">40</a>], as well as more global aplasia [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Thionamides</span><span class="headingEndMark"> — </span>The prevalence of agranulocytosis with thionamide therapy (eg, <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a> [MMI], <a class="drug drug_general" data-topicid="9830" href="/z/d/drug information/9830.html" rel="external">propylthiouracil</a> [PTU], or carbimazole, a drug available in Europe that is completely metabolized to MMI) ranges from 0.2 to 0.5 percent [<a href="#rid41">41-47</a>]. In one study, agranulocytosis was more frequent in older adult patients taking MMI in doses &gt;40 mg/day; in comparison, the prevalence with PTU was dose-independent [<a href="#rid46">46</a>]. In another report, most cases occurred within three months after treatment was begun [<a href="#rid44">44</a>]. However, these findings are not uniform as a Japanese study found that the development of thionamide-induced agranulocytosis was independent of dose, age, duration of treatment, or second exposure to the thionamide [<a href="#rid47">47</a>]. Controversy exists as to the value of monitoring white blood cell counts in patients taking these medications. (See <a class="local">'Prevention and screening'</a> below.)</p><p class="headingAnchor" id="H11"><span class="h2">Sulfasalazine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">Sulfasalazine</a>, an agent that is reduced by the bacterial enzyme azoreductase to sulfapyridine and 5-aminosalicylic acid, is used in the treatment of inflammatory bowel disease and rheumatoid arthritis. (See  <a class="medical medical_review" href="/z/d/html/4065.html" rel="external">"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease"</a> and  <a class="medical medical_review" href="/z/d/html/7524.html" rel="external">"Sulfasalazine: Pharmacology, administration, and adverse effects in the treatment of rheumatoid arthritis"</a>.)</p><p>Most episodes of neutropenia, which occur in 1 to 2 percent of patients treated with <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a>, are mild and transient, although life-threatening agranulocytosis can occur [<a href="#rid48">48-51</a>]. The estimated frequency of agranulocytosis is 0.6 percent in patients with arthritis and 0.06 percent in those with inflammatory bowel disease [<a href="#rid49">49</a>]. In this review, there were no cases of agranulocytosis following the use of <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">mesalamine</a>, a related 5-aminosalicylic acid derivative. Serious episodes of agranulocytosis are usually observed within the first three months of therapy and often within the first six weeks [<a href="#rid51">51</a>].</p><p>The adverse effect of <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a> on white cells may be either idiosyncratic or dose-dependent. Distinguishing the different mechanisms is clinically important. Agranulocytosis caused by a hypersensitivity reaction requires drug discontinuation without rechallenge; by comparison, some investigators feel that benign neutropenia can be treated with dose reduction.</p><p>Other sulfa drugs, such as <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, also are common causes of agranulocytosis [<a href="#rid6">6,52,53</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Ticlopidine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">Ticlopidine</a> is a thienopyridine antiplatelet drug that is effective in stroke patients and in preventing coronary stent thrombosis after coronary stenting. However, it causes neutropenia at a rate of approximately 2.4 percent, usually within the first three months of therapy [<a href="#rid54">54-56</a>]. Fatal agranulocytosis with thrombocytopenia has been seen as early as three to four weeks after starting ticlopidine [<a href="#rid57">57,58</a>]. Data from the Food and Drug Administration's MedWatch program collected between 1992 and 1997 revealed 116 cases of agranulocytosis associated with ticlopidine, with 22 deaths [<a href="#rid59">59</a>].</p><p>Because of the above risks, which are not seen or seen much less often with <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a>, clopidogrel has become the thienopyridine of choice. When <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">ticlopidine</a> is used, it is essential to obtain a complete blood count with platelet count and white cell differential every two weeks for four months after the initiation of therapy.</p><p class="headingAnchor" id="H7617817"><span class="h2">Rituximab</span><span class="headingEndMark"> — </span>Neutropenia has been observed following use of the chimeric anti-CD20 monoclonal antibody <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> for both malignant (eg, lymphoproliferative) and non-malignant (eg, rheumatic) disease [<a href="#rid60">60,61</a>]. It may be severe (grades III-IV), is associated with the period of B cell depletion, with fever and infection in about 17 percent of the cases, and occurs a median of 38 to 175 days following the last rituximab dose, with a median duration of 5 to 77 days [<a href="#rid60">60,62</a>]. Retreatment with rituximab may result in recurrent episodes. The mechanism behind “late onset neutropenia” is unknown, although direct toxicity is thought to be unlikely [<a href="#rid63">63,64</a>]. Myeloid maturation arrest has been noted in some cases [<a href="#rid60">60</a>].</p><p>Polymorphisms in FCGR3A (FcgammaRIIIa), a low-affinity receptor capable of binding to the Fc portion of complexed but not monomeric IgG, have been implicated in this process [<a href="#rid65">65,66</a>]. This issue was evaluated in a retrospective analysis of 115 patients with diffuse large B cell lymphoma treated with CHOP plus <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> chemotherapy, following which 6 percent developed LON [<a href="#rid67">67</a>]. LON developed in 50, 7, and 2 percent of those with the VV, VF, and FF FCGR3A polymorphisms, respectively.</p><p>Of interest, in a review of 92 patients who developed late onset neutropenia, all except one had achieved a complete remission from their underlying lymphoproliferative disorder [<a href="#rid68">68</a>]. <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> was discontinued from further chemotherapy regimens in many of these patients with no negative impact on their final outcome.</p><p>The role of growth factors once late onset neutropenia appears is ill-defined and the decision to use them should be made on a case-by-case basis. In the series of 11 patients with rheumatologic disease who developed late onset neutropenia following treatment with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, the median duration of neutropenia was nine days (range: 4 to 20 days), with nadir absolute neutrophil counts ranging from 100 to 1200/microL (median 700/microL) [<a href="#rid60">60</a>]. Seven of the 11 patients were hospitalized, six with sepsis and one with febrile neutropenia; all required treatment with intravenous antibiotics and six of the seven received treatment with G-CSF. While the neutrophil count recovered in all cases, sustained neutropenia lasting 19 to 20 days was observed in three of the patients who did not receive treatment with G-CSF.</p><p>Other biotherapies (<a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a>, <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a>, <a class="drug drug_general" data-topicid="8906" href="/z/d/drug information/8906.html" rel="external">canakinumab</a>, <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a>, <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a> <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>) have also been implicated as causing neutropenia [<a href="#rid69">69</a>].</p><p class="headingAnchor" id="H1874810626"><span class="h2">Quinine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">Quinine</a>, which is occasionally used to treat malaria or leg cramps and is an ingredient in certain beverages, is occasionally implicated in causing neutropenia. When it occurs, neutropenia is often accompanied by other organ-system findings that may include thrombocytopenia, microangiopathic hemolytic anemia, rash, acute kidney injury, fever/chills, and others. The mechanism in many cases appears to be an acute, immune-mediated reaction to the drug. Evidence to support these associations was evaluated in a 2016 systematic review of published reports, which found neutropenia in 24 (17 percent) of the 142 patients who had an immune-mediated quinine reaction.</p><p>Of <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">quinine</a> reactions, drug-induced thrombotic microangiopathy (DITMA) and drug-induced immune thrombocytopenia (DITP) are more common than drug-induced neutropenia. Additional information about sources of quinine and typical findings in individuals with an adverse drug reaction to quinine is presented separately. (See  <a class="medical medical_review" href="/z/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)", section on 'Quinine'</a> and  <a class="medical medical_review" href="/z/d/html/6674.html" rel="external">"Drug-induced immune thrombocytopenia", section on 'Medication review/temporal relationship'</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Cocaine and heroin</span><span class="headingEndMark"> — </span>The use of heroin and cocaine has been associated with agranulocytosis, likely because these illicit agents were adulterated with levamisole [<a href="#rid70">70-73</a>]. (See  <a class="medical medical_review" href="/z/d/html/303.html" rel="external">"Cocaine: Acute intoxication", section on 'Levamisole'</a>.) </p><p class="headingAnchor" id="H2754919427"><span class="h2">Miscellaneous agents</span><span class="headingEndMark"> — </span>Along with the antimicrobial agents noted in the table  (<a class="graphic graphic_table graphicRef65507" href="/z/d/graphic/65507.html" rel="external">table 2</a>), <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">oseltamivir</a> has now been associated with neutropenia in adults and children and the antihistamine <a class="drug drug_general" data-topicid="8860" href="/z/d/drug information/8860.html" rel="external">chlorpheniramine</a> has been associated with neutropenia and agranulocytosis [<a href="#rid74">74</a>].</p><p class="headingAnchor" id="H14"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>There are two basic mechanisms by which drugs cause neutropenia and/or agranulocytosis:</p><p class="bulletIndent1"><span class="glyph">●</span>Immune mediated destruction of circulating neutrophils by drug-dependent or drug-induced antibodies</p><p class="bulletIndent1"><span class="glyph">●</span>Direct toxic effects upon marrow granulocytic precursors.</p><p></p><p>Idiosyncratic drug reactions are thought to be immune mediated. The onset is usually delayed and can occur as much as a month after the drug has been stopped. As might be expected, the onset of reaction with re-challenge can be much shorter [<a href="#rid2">2</a>].</p><p>Both mechanisms appear to be mediated by reactive metabolites [<a href="#rid75">75</a>]. The enzyme system most likely responsible for the formation of reactive metabolites is the NADPH oxidase/myeloperoxidase system found in neutrophils and monocytes [<a href="#rid2">2</a>]. Drugs that are known to be oxidized to reactive metabolites by this system, and which have been associated with agranulocytosis, include <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>, sulfonamides, <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>, <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">indomethacin</a>, and amodiaquine [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H15"><span class="h2">Immune-mediated destruction</span><span class="headingEndMark"> — </span>The current hypothesis of immune-mediated drug-induced agranulocytosis suggests that the drug, or more commonly a reactive metabolite of the drug, irreversibly binds to the neutrophil membrane. In some cases, the reactive metabolite results in the production of antibodies or T cells directed against the altered membrane structure; in others, true antineutrophil autoantibodies are produced that do not require the presence of the drug [<a href="#rid76">76</a>].</p><p>Examples of drugs that bind to the neutrophil membrane and act as haptens in the production of autoantibodies are <a class="drug drug_general" data-topicid="9830" href="/z/d/drug information/9830.html" rel="external">propylthiouracil</a> (PTU), the antimalarial drug amodiaquine and one of its major metabolites, mono-desethyl amodiaquine, and <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a> [<a href="#rid2">2,20,21,25,42</a>].</p><p>With PTU, highly reactive oxidative products are generated using activated neutrophil myeloperoxidase/hydrogen peroxide/chloride. The products, propyl-thioester, sulfinic acid, and sulfonic acid are all thought to be reactive and form macromolecules that bind covalently to the neutrophil membrane [<a href="#rid2">2</a>]. This macromolecular complex can then induce antibodies capable of binding to the haptenized membrane, leading to the phagocytic destruction of the sensitized cell. Cytotoxicity in one patient was demonstrated to be mediated by a complement-dependent IgM antibody [<a href="#rid42">42</a>].</p><p>Dipyrone, a pyrazolone analgesic, can also induce the production of antineutrophil antibodies [<a href="#rid77">77</a>]. The drug was banned by the United States FDA in 1977 because of a high risk of agranulocytosis, but is still available in some countries [<a href="#rid6">6,77,78</a>].</p><p>Antineutrophil antibodies can be demonstrated by a variety of techniques in most cases of immune-mediated drug-induced agranulocytosis [<a href="#rid79">79</a>]. Laboratory demonstration of antibody binding to target cells often requires the presence of the suspect drug or its metabolites [<a href="#rid2">2</a>]. </p><p class="headingAnchor" id="H16"><span class="h2">Direct and indirect toxicity</span><span class="headingEndMark"> — </span>Some drugs can directly damage myeloid precursors. As an example, detoxification of many nonpolar compounds requires conversion to a chemically reactive intermediate that may bind to nuclear material or cytoplasmic proteins, causing direct toxicity [<a href="#rid75">75</a>]. This mechanism has been described with phenothiazines, in particular <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">chlorpromazine</a> and <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">procainamide</a> [<a href="#rid24">24,80</a>], <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>, and <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> [<a href="#rid81">81-83</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">Clozapine</a> is oxidized by granulocytes to a nitrenium ion formed by chlorination of the nitrogen bridge between the two aromatic rings [<a href="#rid81">81</a>]. This metabolite binds covalently and irreversibly to, and is toxic to, neutrophils and their bone marrow precursors [<a href="#rid82">82</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">Dapsone</a> is metabolized to a highly reactive hydroxylamine which is toxic to bone marrow myeloid cells [<a href="#rid83">83</a>]. In one study over a 17-year period, agranulocytosis was estimated to develop in 1 of 240 to 425 patients receiving dapsone therapy [<a href="#rid28">28</a>].</p><p></p><p>Specific drug-induced reductions in the number and growth of colony forming units can be seen by culture of bone marrow aspirates from affected patients with and without the drug in the medium [<a href="#rid84">84</a>].</p><p class="headingAnchor" id="H17"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Most cases of severe neutropenia or agranulocytosis present within the first six months and usually within the first three months after beginning the offending drug [<a href="#rid1">1,3,28,44,48,51,85</a>]. As an example, a review of the literature concerning vancomycin-induced neutropenia indicated that most cases occurred after a minimum of seven days of treatment, with the majority occurring at least 20 days after initiation of treatment [<a href="#rid86">86</a>]. Many patients are asymptomatic at the time that severe neutropenia is detected, particularly if the patient is being monitored for early detection [<a href="#rid44">44</a>].</p><p>The clinical presentation is usually oral ulcerations with or without fever. As the onset of agranulocytosis can be abrupt, sepsis can be the presentation [<a href="#rid39">39,40</a>]. Thus, it is critical that all patients taking drugs that can cause agranulocytosis be counseled about this complication and instructed to stop the medication and seek medical attention immediately if such symptoms occur.</p><p>Propensity to infection in neutropenic patients is related to adequacy of the marrow reserve pool, and, in patients with decreased reserve, to the ANC (<a class="calc calc_professional" href="/z/d/html/13483.html" rel="external">calculator 1</a>) and the duration of neutropenia. In a systematic review of patients with severe neutropenia induced by nonchemotherapy drugs, fatal complications were more frequent in patients with absolute neutrophil counts of &lt;100 compared with 100 to 500 cells/microL (10 versus 3 percent) [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/8375.html" rel="external">"Overview of neutropenia in children and adolescents"</a>.)</p><p>The clinical presentation depends in part upon the etiology and pathogenesis of drug-induced neutropenia or agranulocytosis. (See  <a class="medical medical_review" href="/z/d/html/8375.html" rel="external">"Overview of neutropenia in children and adolescents"</a>.) The duration of the process before onset of symptoms may depend in part on the mechanism of the neutropenia:</p><p class="bulletIndent1"><span class="glyph">●</span>Immune-mediated destruction may present days to weeks after beginning the drug, often with acute and explosive symptoms. Rechallenge, or inadvertent subsequent administration, is associated with a prompt recurrence even with low doses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When direct or indirect toxicity is the operative mechanism, the presentation may be delayed for months. The neutropenia is often asymptomatic or presents with an insidious onset. Rechallenge requires both a latent period and high drug doses before recurrence is observed.</p><p></p><p class="headingAnchor" id="H20"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis in a patient in whom the predominant abnormality is neutropenia or agranulocytosis includes other causes of acquired neutropenia. The diagnosis may be suspected from the history and is established by bone marrow examination and, when relevant, other tests. (See  <a class="medical medical_review" href="/z/d/html/8375.html" rel="external">"Overview of neutropenia in children and adolescents"</a> and  <a class="medical medical_review" href="/z/d/html/90654.html" rel="external">"Approach to the adult with unexplained neutropenia", section on 'Causes of neutropenia'</a>.)</p><p>Among neutropenic patients who present with infection, it may not be clear whether the infection is due to, or the cause of, the neutropenia. This may be a very important distinction to make, particularly if the medication is critical to the patient’s care. As certain viral infections can be associated with neutropenia, it would be problematic to permanently discontinue use of an important drug on the mistaken assumption that it is the cause of the neutropenia. Bone marrow examination can be particularly helpful in this case. If the marrow cellularity is normal with a late myeloid arrest, the danger from neutropenia is likely much less, and re-challenge or even continuation with careful monitoring may be possible. (See  <a class="medical medical_review" href="/z/d/html/8372.html" rel="external">"Infectious causes of neutropenia"</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">PREVENTION AND SCREENING</span></p><p class="headingAnchor" id="H22"><span class="h2">Overview</span><span class="headingEndMark"> — </span>There is no effective way to detect the rare patient at high risk for drug-induced severe neutropenia or agranulocytosis. Monitoring of the white blood cell count and white cell differential in order to permit early detection has been used for several drug regimens, such as <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> and thionamides [<a href="#rid3">3,44</a>].</p><p>However, the benefit of monitoring is uncertain. Routine use remains controversial due to the low incidence of agranulocytosis and the expense of repeated white blood cell and differential counts.</p><p>In favor of such programs are several studies indicating detection of a large number of patients prior to the development of symptomatic infection, thereby reducing morbidity and mortality. Also in favor of screening is the rapid resolution of neutropenia, often within one to two weeks, once the drug has been discontinued (see <a class="local">'Treatment'</a> below).</p><p>Prophylactic monitoring of the white blood cell count and differential has been evaluated primarily with drugs associated with the highest risk of agranulocytosis, namely <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> and thionamides.</p><p class="headingAnchor" id="H23"><span class="h2">Clozapine screening programs</span><span class="headingEndMark"> — </span>The efficacy of prospectively monitoring the white blood cell count during <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> therapy has been evaluated in two large series:</p><p class="bulletIndent1"><span class="glyph">●</span>After <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> became available in the United States, weekly monitoring of the white blood cell count and differential was required for continued therapy [<a href="#rid3">3</a>]. At 1.5 years, the cumulative incidence of agranulocytosis was 0.9 percent. Two of the 73 patients who developed this complication died of infectious causes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In 4061 Australian patients who were prospectively monitored, the overall incidence of agranulocytosis or neutropenia was 2.6 percent, while the incidence of agranulocytosis was 0.9 percent [<a href="#rid87">87</a>]. There were no deaths from complications of neutropenia or agranulocytosis.</p><p></p><p>Weekly monitoring of the white blood cell count and differential during the first six months is required in the United States for all patients taking this agent. Details concerning frequency of monitoring and when to interrupt or discontinue this medication are presented separately. (See  <a class="medical medical_review" href="/z/d/html/14772.html" rel="external">"Schizophrenia in adults: Guidelines for prescribing clozapine", section on 'Neutrophil count'</a>.)</p><p class="headingAnchor" id="H1033971"><span class="h2">Deferiprone screening</span><span class="headingEndMark"> — </span>Complete blood counts at 7 to 10-day intervals are currently recommended for all patients taking <a class="drug drug_general" data-topicid="17092" href="/z/d/drug information/17092.html" rel="external">deferiprone</a>, and the FDA approval requires that all physicians prescribing this medication counsel patients regarding its use and the risks of fever and neutropenia. Most experienced clinicians agree with this at least for the first year of treatment, although the efficacy of such monitoring has been questioned [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H24"><span class="h2">Thionamides</span><span class="headingEndMark"> — </span>A study from Japan evaluated the efficacy of routine monitoring of the white blood cell count in 15,398 patients with Graves' disease receiving thionamide therapy over a 12-year period [<a href="#rid44">44</a>]. An ANC ≤500/microL occurred in 55 patients (0.4 percent), and was detected in the absence of infection in 43, 14 of whom became symptomatic several days after withdrawal of the drug despite antimicrobial therapy.</p><p>Most clinicians in the United States do not recommend periodic monitoring of the white blood cell count during thionamide therapy. Instead, we advise patients taking a thionamide to have a white blood cell count with differential at the earliest sign of a sore throat or other infection, and to discontinue the drug until the result is available. (See  <a class="medical medical_review" href="/z/d/html/7875.html" rel="external">"Thionamides: Side effects and toxicities"</a>.)</p><p class="headingAnchor" id="H26"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H27"><span class="h2">Withdrawal of the offending agent</span><span class="headingEndMark"> — </span>Once severe neutropenia or agranulocytosis is documented in association with a putative offending drug, the drug should be withdrawn regardless of whether the patient is symptomatic. However, some patients will be taking multiple drugs and identifying the possible offending agent may be difficult [<a href="#rid1">1,88</a>].</p><p>Neutropenia usually resolves within one to three weeks after cessation of the offending drug, but there is substantial interpatient variability [<a href="#rid85">85,88,89</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In one study of 63 episodes in 61 patients, for example, the mean time to recovery was 12 days with a range of 3 to 56 days [<a href="#rid88">88</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another series of 10 patients with thionamide-induced agranulocytosis, the median recovery time was 15 days with a range of 5 to 31 days [<a href="#rid89">89</a>].</p><p></p><p class="headingAnchor" id="H28"><span class="h2">Treatment of associated infection</span><span class="headingEndMark"> — </span>Bone marrow aspiration and biopsy may be helpful, although an isolated agranulocytosis in a patient taking a high-risk drug may, in some cases, be treated without bone marrow examination. If the patient is febrile, cultures of blood, urine, sputum, and other suspected sites of infection should be taken and the patient should be started on broad-spectrum intravenous antibiotics. (See  <a class="medical medical_review" href="/z/d/html/16139.html" rel="external">"Diagnostic approach to the adult cancer patient with neutropenic fever"</a> and  <a class="medical medical_review" href="/z/d/html/16708.html" rel="external">"Overview of neutropenic fever syndromes"</a>.)</p><p>Older age, sepsis, shock, and renal failure are poor prognostic factors [<a href="#rid90">90</a>].</p><p class="headingAnchor" id="H29"><span class="h2">Granulocyte colony-stimulating factor</span><span class="headingEndMark"> — </span>Treatment of drug-induced agranulocytosis with granulocyte colony-stimulating factor (G-CSF) is generally associated with shorter recovery times, less antibiotic use, and shorter length of hospitalization compared with historic or concurrent controls, based on small uncontrolled studies [<a href="#rid8">8,79,91-97</a>]. A small, randomized trial found no significant differences in recovery time, but it used subtherapeutic doses of G-CSF. </p><p class="bulletIndent1"><span class="glyph">●</span>In one report, recovery to an absolute neutrophil count (ANC) &gt;1000/microL occurred within one to 15 days (median four days) after initiation of G-CSF in doses of 4 to 10 mcg/kg per day [<a href="#rid79">79</a>]. Seven of the 22 patients had received aggressive antibiotic and/or antifungal treatment for seven or more days before initiation of G-CSF. Two deaths occurred from causes unrelated to G-CSF use. Complete recovery occurred in the remaining 20 patients, with clinical improvement coincident with normalization of the ANC.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A second study evaluated the effects of G-CSF on recovery at four and 24 hours after injection in 37 patients [<a href="#rid92">92</a>]. In 29 patients (25 with mild neutropenia, ie, ANC 500 to 1000/microL), recovery from granulocytopenia occurred within four hours and remained normal thereafter. In the remaining eight patients, daily G-CSF injections were required for 2 to 11 days. Recovery within four hours suggests that bone marrow suppression was not present, but rather that neutrophils were being released by G-CSF from a storage pool in the marrow.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A trial that randomized 24 patients with drug-induced neutropenia to G-CSF versus no treatment reported no difference in time to recovery of ANC to &gt;500/microL, but it used subtherapeutic doses of G-CSF (100 to 250 mcg subcutaneously daily) [<a href="#rid98">98</a>]. </p><p></p><p>Although their efficacy is not conclusively proven, growth factors have minimal toxicity in this setting. In spite of the lack of evidence of their efficacy in drug-induced neutropenia outside of the oncology setting [<a href="#rid75">75</a>], it seems likely that most patients with agranulocytosis will receive these drugs. G-CSF can be given (at the recommended dose of 5 mcg/kg per day) subcutaneously, empirically, to patients with significant drug-induced neutropenia who are ill and suspected of having reduced marrow reserve. (See  <a class="medical medical_review" href="/z/d/html/8375.html" rel="external">"Overview of neutropenia in children and adolescents"</a>.) Treatment with G-CSF can be discontinued when the total white blood cell count exceeds 10,000/microL [<a href="#rid97">97</a>].</p><p>Availability of longer-lasting pegylated G-CSF (<a class="drug drug_general" data-topicid="10154" href="/z/d/drug information/10154.html" rel="external">pegfilgrastim</a>) provides similar benefits as <a class="drug drug_general" data-topicid="8446" href="/z/d/drug information/8446.html" rel="external">filgrastim</a> with a simpler, less frequent, dosing regimen. However, such agents may be associated with increased bone pain and significant leukocytosis in patients who have a short duration of neutropenia. (See  <a class="medical medical_review" href="/z/d/html/16889.html" rel="external">"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/16889.html" rel="external">"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation", section on 'Long-acting agents'</a>.)</p><p class="headingAnchor" id="H2134892605"><span class="h1">AGRANULOCYTOSIS</span><span class="headingEndMark"> — </span>Agranulocytosis is a rare condition with a reported incidence ranging from 1 to 5 cases per million population per year [<a href="#rid99">99-105</a>]. An association with medication use can be found in about 70 percent of cases [<a href="#rid101">101</a>].</p><p class="headingAnchor" id="H1832331208"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>Specific risk factors for agranulocytosis were evaluated in a prospective survey performed by the International Aplastic Anemia and Agranulocytosis Study (IAAAS) in Europe and Israel from 1980 to 1986 [<a href="#rid106">106,107</a>]. The following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>The incidence rose sharply with age; only 10 percent of cases occurred in children and young adults, while more than 50 percent of cases occurred in patients over age 50.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Agranulocytosis was almost twice as frequent in females, accounting for approximately 70 percent of cases. The sex difference may be due in part to greater consumption of medications at higher risk of causing neutropenia by adult females. This hypothesis is supported by the lack of preponderance of agranulocytosis in female children [<a href="#rid108">108</a>]. There may, however, be a true increase in incidence in females. In a study of 11,555 patients receiving the atypical antipsychotic agent <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>, the risk of agranulocytosis was significantly higher among females [<a href="#rid3">3</a>].</p><p></p><p>Other risk factors for agranulocytosis include [<a href="#rid79">79</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A possible increase in risk in patients with infectious mononucleosis [<a href="#rid109">109</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Impaired drug excretion in the urine due to renal failure or the concomitant use of <a class="drug drug_general" data-topicid="9812" href="/z/d/drug information/9812.html" rel="external">probenecid</a> in patients taking <a class="drug drug_general" data-topicid="9196" href="/z/d/drug information/9196.html" rel="external">captopril</a> [<a href="#rid110">110</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Underlying autoimmune disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Combination therapy with an angiotensin converting enzyme inhibitor and interferon may be associated with a particularly high risk of severe neutropenia. In a series of patients with mixed cryoglobulinemia who were treated with interferon, severe neutropenia developed within a few days in all three patients also receiving an ACE inhibitor but in none of 35 patients treated with interferon alone [<a href="#rid4">4</a>].</p><p></p><p>There is evidence for genetic susceptibility in certain populations.</p><p class="bulletIndent1"><span class="glyph">●</span>The HLA-B38 phenotype and the combined alleles DR4 and DQw3, which occur frequently in Ashkenazi Jews, occur with increased frequency in patients with clozapine-induced agranulocytosis [<a href="#rid5">5</a>]. The associated gene within the MHC region appears to be marked by variants of the heat shock protein 70 gene [<a href="#rid111">111</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among Japanese patients with Graves' disease, the HLA DRB1*08032 allele appears to be strongly associated with susceptibility to methimazole-induced agranulocytosis [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Agranulocytosis secondary to treatment with levamisole, an agent no longer available in North America for human use, has been associated with presence of HLA-B27 [<a href="#rid70">70</a>]. This agent has reappeared as a cause of agranulocytosis or severe neutropenia as a result of its being added to cocaine and heroin, perhaps to potentiate its euphoric effects [<a href="#rid71">71,72,112</a>]. (See <a class="local">'Cocaine and heroin'</a> above.)</p><p></p><p class="headingAnchor" id="H3134427330"><span class="h2">Prognosis</span><span class="headingEndMark"> — </span>A number of adverse prognostic factors have been reported for patients with agranulocytosis. These include [<a href="#rid1">1,2,97</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Age &gt;65 years</p><p class="bulletIndent1"><span class="glyph">●</span>Absolute neutrophil count at the time of diagnosis &lt;100/microL</p><p class="bulletIndent1"><span class="glyph">●</span>Development of severe intercurrent infection (eg, septicemia, septic shock)</p><p class="bulletIndent1"><span class="glyph">●</span>Pre-existing comorbidities (eg, renal, cardiac, respiratory, systemic inflammatory diseases)</p><p></p><p class="headingAnchor" id="H600682214"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/105460.html" rel="external">"Society guideline links: Neutropenic fever in adults with cancer"</a>.)</p><p class="headingAnchor" id="H16196605"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/82906.html" rel="external">"Patient education: Neutropenia (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H30"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions:</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neutropenia</strong> – Absolute neutrophil count (ANC) &lt;1500/microL; calculated using white blood cell count (WBC) and percentage of polymorphonuclear cells (PMNs) and bands (<a class="calc calc_professional" href="/z/d/html/13483.html" rel="external">calculator 1</a>):</p><p></p><p class="bulletIndent3">ANC = (WBC/microL] x percent [PMNs + bands]) ÷ 100</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Agranulocytosis</strong> – Absence of granulocytes (ie, ANC = 0), but the term is often used loosely to indicate severe neutropenia (ie, ANC &lt;100, &lt;200/microL).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug-induced agranulocytosis</strong> – Idiosyncratic drug reactions (IDR) are uncommon (eg, 1/10,000 to 1/100,000). </p><p></p><p class="bulletIndent1">Drugs that are associated with high risk for agranulocytosis  (<a class="graphic graphic_table graphicRef65507" href="/z/d/graphic/65507.html" rel="external">table 2</a>) include: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clozapine</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antithyroid drugs</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Sulfasalazine</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ticlopidine</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other</strong> – Antibiotics, angiotensin-converting enzyme (ACE) inhibitors, H2 blockers, nonsteroidal anti-inflammatory drugs (NSAIDS), amodiaquine, antiarrhythmic drugs, <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>, and <a class="drug drug_general" data-topicid="17092" href="/z/d/drug information/17092.html" rel="external">deferiprone</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanisms</strong> – There are two basic mechanisms of drug-induced neutropenia:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immune</strong> – Immune-mediated destruction of neutrophils (by drug-dependent or drug-induced antibodies).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Toxicity</strong> – Direct toxic effects on marrow granulocytic precursors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Presentation</strong> – Most patients have oral ulcerations, with or without fever; if the onset is abrupt, the patient may present with a severe infection/sepsis. Neutropenia usually begins three to six months after beginning the offending drug, but the interval may vary with the cause (eg, days to weeks with immune-mediated, but months for direct toxicity).  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Suspected in a patient with fever or mouth sores with sudden and/or unexpected neutropenia weeks to months after beginning a drug. </p><p></p><p class="bulletIndent1">Diagnosis is based on neutropenia in the proper clinical context; bone marrow examination is <strong>not</strong> required. The diagnosis is more likely with low/absent ANC without anemia or thrombocytopenia and when the ANC normalizes after withdrawal of the offending agent. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – Concomitant viral infection, nutritional deficiency (eg, copper or vitamin B12 deficiency), other acquired and inherited disorders. (See  <a class="medical medical_review" href="/z/d/html/8375.html" rel="external">"Overview of neutropenia in children and adolescents"</a> and  <a class="medical medical_review" href="/z/d/html/90654.html" rel="external">"Approach to the adult with unexplained neutropenia", section on 'Causes of neutropenia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Drug withdrawal</strong> – The suspected drug should be withdrawn, whether symptomatic or not. Neutropenia usually resolves within one to three weeks after drug cessation, but timing varies.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cytokine support</strong> – For symptomatic neutropenia, we generally administer granulocyte colony-stimulating factor (G-CSF) to shorten recovery time, reduce antibiotic use, and decrease length of hospitalization.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention/screening</strong> – Patients receiving a medication known to cause neutropenia should be instructed to stop the medication and seek immediate medical attention if they develop mouth sores/other mucosal ulcerations and/or fever. </p><p></p><p class="bulletIndent1">For certain drugs (eg, <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>, thionamides), monitoring the WBC count/differential permits early detection. (See <a class="local">'Prevention and screening'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Agranulocytosis</strong> – A rare condition (eg, 1 to 5 cases per million population/year); suspected drugs are identified in two-thirds of patients. (See <a class="local">'Agranulocytosis'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Risk factors</strong> – Incidence increases with age, in females, and in association with autoimmune conditions and certain human leukocyte antigen (HLA) genotypes. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prognostic factors</strong> – Worse outcomes are associated with age &gt;65 years, ANC &lt;100/microL at diagnosis, severe intercurrent infection, and comorbid conditions.</p><p></p><p class="headingAnchor" id="H620967820"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges the late Laurence A Boxer, MD, for his previous role as a section editor for this topic.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 2007; 146:657.</a></li><li><a class="nounderline abstract_t">Johnston A, Uetrecht J. Current understanding of the mechanisms of idiosyncratic drug-induced agranulocytosis. Expert Opin Drug Metab Toxicol 2015; 11:243.</a></li><li><a class="nounderline abstract_t">Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993; 329:162.</a></li><li><a class="nounderline abstract_t">Casato M, Pucillo LP, Leoni M, et al. Granulocytopenia after combined therapy with interferon and angiotensin-converting enzyme inhibitors: evidence for a synergistic hematologic toxicity. Am J Med 1995; 99:386.</a></li><li><a class="nounderline abstract_t">Yunis JJ, Lieberman J, Yunis EJ. Major histocompatibility complex associations with clozapine-induced agranulocytosis. The USA experience. Drug Saf 1992; 7 Suppl 1:7.</a></li><li><a class="nounderline abstract_t">van der Klauw MM, Goudsmit R, Halie MR, et al. A population-based case-cohort study of drug-associated agranulocytosis. Arch Intern Med 1999; 159:369.</a></li><li><a class="nounderline abstract_t">Andrès E, Zimmer J, Mecili M, et al. Clinical presentation and management of drug-induced agranulocytosis. Expert Rev Hematol 2011; 4:143.</a></li><li><a class="nounderline abstract_t">Chia HM, Kalra L, Lakhani AK, Samaratunga IR. Filgrastim for low-dose, captopril-induced agranulocytosis. Lancet 1993; 342:304.</a></li><li><a class="nounderline abstract_t">Elis A, Lishner M, Lang R, Ravid M. Agranulocytosis associated with enalapril. DICP 1991; 25:461.</a></li><li><a class="nounderline abstract_t">Aymard JP, Aymard B, Netter P, et al. Haematological adverse effects of histamine H2-receptor antagonists. Med Toxicol Adverse Drug Exp 1988; 3:430.</a></li><li><a class="nounderline abstract_t">List AF, Beaird DH, Kummet T. Ranitidine-induced granulocytopenia: recurrence with cimetidine administration. Ann Intern Med 1988; 108:566.</a></li><li><a class="nounderline abstract_t">Brenner LO. Agranulocytosis and ranitidine. Ann Intern Med 1986; 104:896.</a></li><li><a class="nounderline abstract_t">Mamus SW, Burton JD, Groat JD, et al. Ibuprofen-associated pure white-cell aplasia. N Engl J Med 1986; 314:624.</a></li><li><a class="nounderline abstract_t">Cramer RL, Aboko-Cole VC, Gualtieri RJ. Agranulocytosis associated with etodolac. Ann Pharmacother 1994; 28:458.</a></li><li><a class="nounderline abstract_t">Muroi K, Ito M, Sasaki R, et al. Treatment of drug-induced agranulocytosis with granulocyte-colony stimulating factor. Lancet 1989; 2:55.</a></li><li><a class="nounderline abstract_t">Colomina P, Garcia S. Agranulocytosis caused by diclofenac. DICP 1989; 23:507.</a></li><li><a class="nounderline abstract_t">García S, Belda J, Linares M, et al. Piroxicam-induced agranulocytosis. Drug Intell Clin Pharm 1988; 22:1003.</a></li><li><a class="nounderline abstract_t">D'Arcy PF. Risks of agranulocytosis and aplastic anemia with analgesic use. Int Pharm J 1987; 1:87.</a></li><li><a class="nounderline abstract_t">Strom BL, Carson JL, Schinnar R, et al. Nonsteroidal anti-inflammatory drugs and neutropenia. Arch Intern Med 1993; 153:2119.</a></li><li><a class="nounderline abstract_t">Rouveix B, Coulombel L, Aymard JP, et al. Amodiaquine-induced immune agranulocytosis. Br J Haematol 1989; 71:7.</a></li><li><a class="nounderline abstract_t">Clarke JB, Neftel K, Kitteringham NR, Park BK. Detection of antidrug IgG antibodies in patients with adverse drug reactions to amodiaquine. Int Arch Allergy Appl Immunol 1991; 95:369.</a></li><li><a class="nounderline abstract_t">Soff GA, Kadin ME. Tocainide-induced reversible agranulocytosis and anemia. Arch Intern Med 1987; 147:598.</a></li><li><a class="nounderline abstract_t">Volosin K, Greenberg RM, Greenspon AJ. Tocainide associated agranulocytosis. Am Heart J 1985; 109:1392.</a></li><li><a class="nounderline abstract_t">Ellrodt AG, Murata GH, Riedinger MS, et al. Severe neutropenia associated with sustained-release procainamide. Ann Intern Med 1984; 100:197.</a></li><li><a class="nounderline abstract_t">Samlowski WE, Frame RN, Logue GL. Flecanide-induced immune neutropenia. Documentation of a hapten-mediated mechanism of cell destruction. Arch Intern Med 1987; 147:383.</a></li><li><a class="nounderline abstract_t">Vincent MD, Clink HM, Coombes RC, et al. Aminoglutethimide (with hydrocortisone) induced agranulocytosis in primary breast cancer. Br Med J (Clin Res Ed) 1985; 291:105.</a></li><li><a class="nounderline abstract_t">Caldwell G, Bradbury A, Toft AD. Aminoglutethimide induced agranulocytosis in breast cancer. Br Med J (Clin Res Ed) 1985; 291:970.</a></li><li><a class="nounderline abstract_t">Hörnsten P, Keisu M, Wiholm BE. The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988. Arch Dermatol 1990; 126:919.</a></li><li><a class="nounderline abstract_t">Piga A, Roggero S, Salussolia I, et al. Deferiprone. Ann N Y Acad Sci 2010; 1202:75.</a></li><li><a class="nounderline abstract_t">Cohen AR, Galanello R, Piga A, et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003; 102:1583.</a></li><li class="breakAll">www.adverse-effects.com/agranulocytosis/case_reports.html (Accessed on October 05, 2011).</li><li><a class="nounderline abstract_t">Ibáñez L, Vidal X, Ballarín E, Laporte JR. Population-based drug-induced agranulocytosis. Arch Intern Med 2005; 165:869.</a></li><li><a class="nounderline abstract_t">Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med 1997; 337:809.</a></li><li><a class="nounderline abstract_t">Gardner I, Zahid N, MacCrimmon D, Uetrecht JP. A comparison of the oxidation of clozapine and olanzapine to reactive metabolites and the toxicity of these metabolites to human leukocytes. Mol Pharmacol 1998; 53:991.</a></li><li><a class="nounderline abstract_t">Naumann R, Felber W, Heilemann H, Reuster T. Olanzapine-induced agranulocytosis. Lancet 1999; 354:566.</a></li><li><a class="nounderline abstract_t">Benedetti F, Cavallaro R, Smeraldi E. Olanzapine-induced neutropenia after clozapine-induced neutropenia. Lancet 1999; 354:567.</a></li><li><a class="nounderline abstract_t">Berdoukas V, Farmaki K, Carson S, et al. Treating thalassemia major-related iron overload: the role of deferiprone. J Blood Med 2012; 3:119.</a></li><li><a class="nounderline abstract_t">Galanello R, Campus S. Deferiprone chelation therapy for thalassemia major. Acta Haematol 2009; 122:155.</a></li><li><a class="nounderline abstract_t">Henter JI, Karlén J. Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia. Blood 2007; 109:5157.</a></li><li><a class="nounderline abstract_t">Masera N, Tavecchia L, Longoni DV, et al. Agranulocytosis due to deferiprone: a case report with cytomorphological and functional bone marrow examination. Blood Transfus 2011; 9:462.</a></li><li><a class="nounderline abstract_t">Tamai H, Sudo T, Kimura A, et al. Association between the DRB1*08032 histocompatibility antigen and methimazole-induced agranulocytosis in Japanese patients with Graves disease. Ann Intern Med 1996; 124:490.</a></li><li><a class="nounderline abstract_t">Guffy MM, Goeken NE, Burns CP. Granulocytotoxic antibodies in a patient with propylthiouracil-induced agranulocytosis. Arch Intern Med 1984; 144:1687.</a></li><li><a class="nounderline abstract_t">Shiran A, Shechner C, Dickstein G. Propylthiouracil-induced agranulocytosis in four patients previously treated with the drug. JAMA 1991; 266:3129.</a></li><li><a class="nounderline abstract_t">Tajiri J, Noguchi S, Murakami T, Murakami N. Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring. Arch Intern Med 1990; 150:621.</a></li><li><a class="nounderline abstract_t">Fincher ME, Fariss BL, Plymate SR, et al. Agranulocytosis and a small dose of methimazole. Ann Intern Med 1984; 101:404.</a></li><li><a class="nounderline abstract_t">Cooper DS, Goldminz D, Levin AA, et al. Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose. Ann Intern Med 1983; 98:26.</a></li><li><a class="nounderline abstract_t">Tamai H, Takaichi Y, Morita T, et al. Methimazole-induced agranulocytosis in Japanese patients with Graves' disease. Clin Endocrinol (Oxf) 1989; 30:525.</a></li><li><a class="nounderline abstract_t">Keisu M, Ekman E. Sulfasalazine associated agranulocytosis in Sweden 1972-1989. Clinical features, and estimation of its incidence. Eur J Clin Pharmacol 1992; 43:215.</a></li><li><a class="nounderline abstract_t">Jick H, Myers MW, Dean AD. The risk of sulfasalazine- and mesalazine-associated blood disorders. Pharmacotherapy 1995; 15:176.</a></li><li><a class="nounderline abstract_t">Farr M, Scott DG, Bacon PA. Side effect profile of 200 patients with inflammatory arthritides treated with sulphasalazine. Drugs 1986; 32 Suppl 1:49.</a></li><li><a class="nounderline abstract_t">Amos RS, Pullar T, Bax DE, et al. Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years. Br Med J (Clin Res Ed) 1986; 293:420.</a></li><li><a class="nounderline abstract_t">Keisu M, Wiholm BE, Palmblad J. Trimethoprim-sulphamethoxazole-associated blood dyscrasias. Ten years' experience of the Swedish spontaneous reporting system. J Intern Med 1990; 228:353.</a></li><li><a class="nounderline abstract_t">Andrès E, Maloisel F. Antibiotic-induced agranulocytosis: a monocentric study of 21 cases. Arch Intern Med 2001; 161:2619.</a></li><li><a class="nounderline abstract_t">Haushofer A, Halbmayer WM, Prachar H. Neutropenia with ticlopidine plus aspirin. Lancet 1997; 349:474.</a></li><li><a class="nounderline abstract_t">Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1:1215.</a></li><li><a class="nounderline abstract_t">Hass WK, Easton JD, Adams HP Jr, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989; 321:501.</a></li><li><a class="nounderline abstract_t">Carlson JA, Maesner JE. Fatal neutropenia and thrombocytopenia associated with ticlopidine. Ann Pharmacother 1994; 28:1236.</a></li><li><a class="nounderline abstract_t">Szto GY, Linnemeier TJ, Ball MW. Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting. Am J Cardiol 1999; 83:138.</a></li><li><a class="nounderline abstract_t">Bennett CL, Davidson CJ, Raisch DW, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. Arch Intern Med 1999; 159:2524.</a></li><li><a class="nounderline abstract_t">Tesfa D, Ajeganova S, Hägglund H, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum 2011; 63:2209.</a></li><li><a class="nounderline abstract_t">Rozman S, Sonc M, Novakovic BJ. Late-onset neutropenia following primary treatment of diffuse large B-cell lymphoma with rituximab-containing therapy. Leuk Lymphoma 2012; 53:1945.</a></li><li><a class="nounderline abstract_t">Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore) 2010; 89:308.</a></li><li><a class="nounderline abstract_t">Grant C, Wilson WH, Dunleavy K. Neutropenia associated with rituximab therapy. Curr Opin Hematol 2011; 18:49.</a></li><li><a class="nounderline abstract_t">Cattaneo C, Spedini P, Casari S, et al. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma 2006; 47:1013.</a></li><li><a class="nounderline abstract_t">Li SC, Chen YC, Evens AM, et al. Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcγRIIIa 158(V/F) polymorphism. Am J Hematol 2010; 85:810.</a></li><li><a class="nounderline abstract_t">Weng WK, Negrin RS, Lavori P, Horning SJ. Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma. J Clin Oncol 2010; 28:279.</a></li><li><a class="nounderline abstract_t">Keane C, Nourse JP, Crooks P, et al. Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma. Intern Med J 2012; 42:1113.</a></li><li><a class="nounderline abstract_t">Hincks I, Woodcock BE, Thachil J. Is rituximab-induced late-onset neutropenia a good prognostic indicator in lymphoproliferatve disorders? Br J Haematol 2011; 153:411.</a></li><li><a class="nounderline abstract_t">Andrès E, Villalba NL, Zulfiqar AA, et al. State of Art of Idiosyncratic Drug-Induced Neutropenia or Agranulocytosis, with a Focus on Biotherapies. J Clin Med 2019; 8.</a></li><li><a class="nounderline abstract_t">Hodinka L, Géher P, Merétey K, et al. Levamisole-induced neutropenia and agranulocytosis: association with HLA B27 leukocyte agglutinating and lymphocytotoxic antibodies. Int Arch Allergy Appl Immunol 1981; 65:460.</a></li><li><a class="nounderline abstract_t">Zhu NY, Legatt DF, Turner AR. Agranulocytosis after consumption of cocaine adulterated with levamisole. Ann Intern Med 2009; 150:287.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Agranulocytosis associated with cocaine use - four States, March 2008-November 2009. MMWR Morb Mortal Wkly Rep 2009; 58:1381.</a></li><li><a class="nounderline abstract_t">Lee KC, Ladizinski B, Federman DG. Complications associated with use of levamisole-contaminated cocaine: an emerging public health challenge. Mayo Clin Proc 2012; 87:581.</a></li><li><a class="nounderline abstract_t">Wei R, Jia LL, Yu YC, et al. Pediatric drug safety signal detection of non-chemotherapy drug-induced neutropenia and agranulocytosis using electronic healthcare records. Expert Opin Drug Saf 2019; 18:435.</a></li><li><a class="nounderline abstract_t">Tesfa D, Keisu M, Palmblad J. Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management. Am J Hematol 2009; 84:428.</a></li><li><a class="nounderline abstract_t">Christie DJ. Specificity of drug-induced immune cytopenias. Transfus Med Rev 1993; 7:230.</a></li><li><a class="nounderline abstract_t">Dorr VJ, Cook J. Agranulocytosis and near fatal sepsis due to 'Mexican aspirin' (dipyrone). South Med J 1996; 89:612.</a></li><li><a class="nounderline abstract_t">Edwards JE, McQuay HJ. Dipyrone and agranulocytosis: what is the risk? Lancet 2002; 360:1438.</a></li><li><a class="nounderline abstract_t">Young NS. Agranulocytosis. JAMA 1994; 271:935.</a></li><li><a class="nounderline abstract_t">Pisciotta AV. Drug-induced agranulocytosis. Peripheral destruction of polymorphonuclear leukocytes and their marrow precursors. Blood Rev 1990; 4:226.</a></li><li><a class="nounderline abstract_t">Uetrecht J, Zahid N, Tehim A, et al. Structural features associated with reactive metabolite formation in clozapine analogues. Chem Biol Interact 1997; 104:117.</a></li><li><a class="nounderline abstract_t">Gerson SL, Meltzer H. Mechanisms of clozapine-induced agranulocytosis. Drug Saf 1992; 7 Suppl 1:17.</a></li><li><a class="nounderline abstract_t">Uetrecht J, Zahid N, Shear NH, Biggar WD. Metabolism of dapsone to a hydroxylamine by human neutrophils and mononuclear cells. J Pharmacol Exp Ther 1988; 245:274.</a></li><li><a class="nounderline abstract_t">Parent-Massin DM, Sensébé L, Léglise MC, et al. Relevance of in vitro studies of drug-induced agranulocytosis. Report of 14 cases. Drug Saf 1993; 9:463.</a></li><li><a class="nounderline abstract_t">Jacobson IM, Kelsey PB, Blyden GT, et al. Sulfasalazine-induced agranulocytosis. Am J Gastroenterol 1985; 80:118.</a></li><li><a class="nounderline abstract_t">Black E, Lau TT, Ensom MH. Vancomycin-induced neutropenia: is it dose- or duration-related? Ann Pharmacother 2011; 45:629.</a></li><li><a class="nounderline abstract_t">Copolov DL, Bell WR, Benson WJ, et al. Clozapine treatment in Australia: a review of haematological monitoring. Med J Aust 1998; 168:495.</a></li><li><a class="nounderline abstract_t">Heit W, Heimpel H, Fischer A, Frickhofen N. Drug-induced agranulocytosis: evidence for the commitment of bone marrow haematopoiesis. Scand J Haematol 1985; 35:459.</a></li><li><a class="nounderline abstract_t">Meyer-Gessner M, Benker G, Lederbogen S, et al. Antithyroid drug-induced agranulocytosis: clinical experience with ten patients treated at one institution and review of the literature. J Endocrinol Invest 1994; 17:29.</a></li><li><a class="nounderline abstract_t">Juliá A, Olona M, Bueno J, et al. Drug-induced agranulocytosis: prognostic factors in a series of 168 episodes. Br J Haematol 1991; 79:366.</a></li><li><a class="nounderline abstract_t">Góra-Tybor J, Krykowski E, Robak T. Treatment of drug-induced agranulocytosis with colony stimulating factors (G-CSF or GM-CSF). Arch Immunol Ther Exp (Warsz) 1996; 44:255.</a></li><li><a class="nounderline abstract_t">Tajiri J, Noguchi S, Murakami N. Usefulness of granulocyte count measurement four hours after injection of granulocyte colony-stimulating factor for detecting recovery from antithyroid drug-induced granulocytopenia. Thyroid 1997; 7:575.</a></li><li><a class="nounderline abstract_t">Wickramanayake PD, Scheid C, Josting A, et al. Use of granulocyte colony-stimulating factor (filgrastim) in the treatment of non-cytotoxic drug-induced agranulocytosis. Eur J Med Res 1995; 1:153.</a></li><li><a class="nounderline abstract_t">Balkin MS, Buchholtz M, Ortiz J, Green AJ. Propylthiouracil (PTU)-induced agranulocytosis treated with recombinant human granulocyte colony-stimulating factor (G-CSF). Thyroid 1993; 3:305.</a></li><li><a class="nounderline abstract_t">Andrès E, Kurtz JE, Martin-Hunyadi C, et al. Nonchemotherapy drug-induced agranulocytosis in elderly patients: the effects of granulocyte colony-stimulating factor. Am J Med 2002; 112:460.</a></li><li><a class="nounderline abstract_t">Mossad SB. Agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 2008; 148:320; author reply 320.</a></li><li><a class="nounderline abstract_t">Andrès E, Maloisel F, Zimmer J. The role of haematopoietic growth factors granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the management of drug-induced agranulocytosis. Br J Haematol 2010; 150:3.</a></li><li><a class="nounderline abstract_t">Fukata S, Kuma K, Sugawara M. Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug-induced agranulocytosis: a prospective study. Thyroid 1999; 9:29.</a></li><li><a class="nounderline abstract_t">Hamerschlak N, Montezuma MP, Bacal N, et al. Retrospective prevalence and incidence of drug-induced agranulocytosis in the city of São Paulo-Brasil. Rev Paul Med 1993; 111:294.</a></li><li><a class="nounderline abstract_t">Strom BL, Carson JL, Schinnar R, et al. Descriptive epidemiology of agranulocytosis. Arch Intern Med 1992; 152:1475.</a></li><li><a class="nounderline abstract_t">Kaufman DW, Kelly JP, Jurgelon JM, et al. Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur J Haematol Suppl 1996; 60:23.</a></li><li><a class="nounderline abstract_t">Billekop K, Mosbech J. [Mortality from agranulocytosis in Denmark during the period 1958-1972]. Ugeskr Laeger 1976; 138:1697.</a></li><li><a class="nounderline abstract_t">Böttiger LE, Furhoff AK, Holmberg L. Drug-induced blood dyscrasias. A ten-year material from the Swedish Adverse Drug Reaction Committee. Acta Med Scand 1979; 205:457.</a></li><li><a class="nounderline abstract_t">Wiholm BE, Emanuelsson S. Drug-related blood dyscrasias in a Swedish reporting system, 1985-1994. Eur J Haematol Suppl 1996; 60:42.</a></li><li><a class="nounderline abstract_t">Kaufman DW, Kelly JP, Issaragrisil S, et al. Relative incidence of agranulocytosis and aplastic anemia. Am J Hematol 2006; 81:65.</a></li><li class="breakAll">Kaufman DW, Kelly JP, Levy M, et al. The Drug Etiology of Agranulocytosis and Aplastic Anemia, Oxford University Press, New York 1991.</li><li><a class="nounderline abstract_t">Kaufman DW, Kelly JP, Levy M, et al. Drug etiology of agranulocytosis: Update of the International Agranulocytosis and Aplastic Anemia Study. Pharmacoepidem Drug Safety 1993; 2:S25.</a></li><li><a class="nounderline abstract_t">Kantero I, Mustala OO, Palva IP. Drug-induced agranulocytosis, with special reference to aminophenazone. IV. Children. Acta Med Scand 1972; 192:327.</a></li><li><a class="nounderline abstract_t">Levy M, Kelly JP, Kaufman DW, Shapiro S. Risk of agranulocytosis and aplastic anemia in relation to history of infectious mononucleosis: a report from the international agranulocytosis and aplastic anemia study. Ann Hematol 1993; 67:187.</a></li><li><a class="nounderline abstract_t">Sinhvi SM, Duchin KL, Willard DA, et al. Renal handling of captopril: effect of probenecid. Clin Pharmacol Ther 1982; 32:182.</a></li><li><a class="nounderline abstract_t">Corzo D, Yunis JJ, Salazar M, et al. The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups. Blood 1995; 86:3835.</a></li><li><a class="nounderline abstract_t">Muirhead TT, Eide MJ. Images in clinical medicine. Toxic effects of levamisole in a cocaine user. N Engl J Med 2011; 364:e52.</a></li></ol></div><div id="topicVersionRevision">Topic 8374 Version 43.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17470834" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Systematic review: agranulocytosis induced by nonchemotherapy drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25424130" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Current understanding of the mechanisms of idiosyncratic drug-induced agranulocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8515788" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7573094" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Granulocytopenia after combined therapy with interferon and angiotensin-converting enzyme inhibitors: evidence for a synergistic hematologic toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1503679" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Major histocompatibility complex associations with clozapine-induced agranulocytosis. The USA experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10030310" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A population-based case-cohort study of drug-associated agranulocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21495924" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical presentation and management of drug-induced agranulocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8101328" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Filgrastim for low-dose, captopril-induced agranulocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2068826" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Agranulocytosis associated with enalapril.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2905759" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Haematological adverse effects of histamine H2-receptor antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3348565" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Ranitidine-induced granulocytopenia: recurrence with cimetidine administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3706952" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Agranulocytosis and ranitidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3945248" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Ibuprofen-associated pure white-cell aplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8038466" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Agranulocytosis associated with etodolac.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2472536" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Treatment of drug-induced agranulocytosis with granulocyte-colony stimulating factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2741485" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Agranulocytosis caused by diclofenac.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3243167" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Piroxicam-induced agranulocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Risks of agranulocytosis and aplastic anemia with analgesic use</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8379803" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Nonsteroidal anti-inflammatory drugs and neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2917131" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Amodiaquine-induced immune agranulocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1959977" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Detection of antidrug IgG antibodies in patients with adverse drug reactions to amodiaquine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3103562" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Tocainide-induced reversible agranulocytosis and anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3923811" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Tocainide associated agranulocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6691661" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Severe neutropenia associated with sustained-release procainamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2434046" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Flecanide-induced immune neutropenia. Documentation of a hapten-mediated mechanism of cell destruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2990631" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Aminoglutethimide (with hydrocortisone) induced agranulocytosis in primary breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3929986" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Aminoglutethimide induced agranulocytosis in breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2360840" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20712776" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Deferiprone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12763939" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12763939" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15851637" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Population-based drug-induced agranulocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9295240" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9614200" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A comparison of the oxidation of clozapine and olanzapine to reactive metabolites and the toxicity of these metabolites to human leukocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10470705" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Olanzapine-induced agranulocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10470706" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Olanzapine-induced neutropenia after clozapine-induced neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23112580" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Treating thalassemia major-related iron overload: the role of deferiprone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19907153" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Deferiprone chelation therapy for thalassemia major.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17344464" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21839013" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Agranulocytosis due to deferiprone: a case report with cytomorphological and functional bone marrow examination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8602707" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Association between the DRB1*08032 histocompatibility antigen and methimazole-induced agranulocytosis in Japanese patients with Graves disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6205633" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Granulocytotoxic antibodies in a patient with propylthiouracil-induced agranulocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1956096" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Propylthiouracil-induced agranulocytosis in four patients previously treated with the drug.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2310281" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6465720" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Agranulocytosis and a small dose of methimazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6687345" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2605789" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Methimazole-induced agranulocytosis in Japanese patients with Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1358622" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Sulfasalazine associated agranulocytosis in Sweden 1972-1989. Clinical features, and estimation of its incidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7624265" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The risk of sulfasalazine- and mesalazine-associated blood disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2877853" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Side effect profile of 200 patients with inflammatory arthritides treated with sulphasalazine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2874863" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2266345" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Trimethoprim-sulphamethoxazole-associated blood dyscrasias. Ten years' experience of the Swedish spontaneous reporting system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11718595" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Antibiotic-induced agranulocytosis: a monocentric study of 21 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9040584" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Neutropenia with ticlopidine plus aspirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2566778" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2761587" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7849334" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Fatal neutropenia and thrombocytopenia associated with ticlopidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10073806" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10573042" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21560117" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22563814" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Late-onset neutropenia following primary treatment of diffuse large B-cell lymphoma with rituximab-containing therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20827108" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21102324" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Neutropenia associated with rituximab therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16840190" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20730791" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcγRIIIa 158(V/F) polymorphism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19933905" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21883784" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21275972" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Is rituximab-induced late-onset neutropenia a good prognostic indicator in lymphoproliferatve disorders?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31480527" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : State of Art of Idiosyncratic Drug-Induced Neutropenia or Agranulocytosis, with a Focus on Biotherapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7251195" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Levamisole-induced neutropenia and agranulocytosis: association with HLA B27 leukocyte agglutinating and lymphocytotoxic antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19153405" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Agranulocytosis after consumption of cocaine adulterated with levamisole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20019655" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Agranulocytosis associated with cocaine use - four States, March 2008-November 2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22677078" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Complications associated with use of levamisole-contaminated cocaine: an emerging public health challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31002530" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Pediatric drug safety signal detection of non-chemotherapy drug-induced neutropenia and agranulocytosis using electronic healthcare records.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19459150" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8241612" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Specificity of drug-induced immune cytopenias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8638202" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Agranulocytosis and near fatal sepsis due to 'Mexican aspirin' (dipyrone).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12433507" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Dipyrone and agranulocytosis: what is the risk?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7509883" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Agranulocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2076470" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Drug-induced agranulocytosis. Peripheral destruction of polymorphonuclear leukocytes and their marrow precursors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9212779" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Structural features associated with reactive metabolite formation in clozapine analogues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1503673" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Mechanisms of clozapine-induced agranulocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3129552" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Metabolism of dapsone to a hydroxylamine by human neutrophils and mononuclear cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8129866" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Relevance of in vitro studies of drug-induced agranulocytosis. Report of 14 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2857524" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Sulfasalazine-induced agranulocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21521866" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Vancomycin-induced neutropenia: is it dose- or duration-related?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9631674" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Clozapine treatment in Australia: a review of haematological monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4089527" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Drug-induced agranulocytosis: evidence for the commitment of bone marrow haematopoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7516356" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Antithyroid drug-induced agranulocytosis: clinical experience with ten patients treated at one institution and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1751364" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Drug-induced agranulocytosis: prognostic factors in a series of 168 episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9017166" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Treatment of drug-induced agranulocytosis with colony stimulating factors (G-CSF or GM-CSF).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9292945" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Usefulness of granulocyte count measurement four hours after injection of granulocyte colony-stimulating factor for detecting recovery from antithyroid drug-induced granulocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9445760" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Use of granulocyte colony-stimulating factor (filgrastim) in the treatment of non-cytotoxic drug-induced agranulocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7509672" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Propylthiouracil (PTU)-induced agranulocytosis treated with recombinant human granulocyte colony-stimulating factor (G-CSF).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11959056" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Nonchemotherapy drug-induced agranulocytosis in elderly patients: the effects of granulocyte colony-stimulating factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18283214" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Agranulocytosis induced by nonchemotherapy drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20151980" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : The role of haematopoietic growth factors granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the management of drug-induced agranulocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10037073" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug-induced agranulocytosis: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8235248" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Retrospective prevalence and incidence of drug-induced agranulocytosis in the city of São Paulo-Brasil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1627027" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Descriptive epidemiology of agranulocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8987237" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Drugs in the aetiology of agranulocytosis and aplastic anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/936324" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : [Mortality from agranulocytosis in Denmark during the period 1958-1972].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/452939" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Drug-induced blood dyscrasias. A ten-year material from the Swedish Adverse Drug Reaction Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8987240" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Drug-related blood dyscrasias in a Swedish reporting system, 1985-1994.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16369972" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Relative incidence of agranulocytosis and aplastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16369972" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Relative incidence of agranulocytosis and aplastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Drug etiology of agranulocytosis: Update of the International Agranulocytosis and Aplastic Anemia Study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5081071" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Drug-induced agranulocytosis, with special reference to aminophenazone. IV. Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8218540" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Risk of agranulocytosis and aplastic anemia in relation to history of infectious mononucleosis: a report from the international agranulocytosis and aplastic anemia study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7047044" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Renal handling of captopril: effect of probenecid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7579351" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21675882" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Images in clinical medicine. Toxic effects of levamisole in a cocaine user.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
